GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

Health officials are reminding the public that antibiotics are ineffective against respiratory infections caused by viruses, ...

Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...

Timely diagnosis of RSV is imperative for optimal patient management; by rapidly identifying RSV infection, health professionals can implement appropriate infection control measures while limiting ...

(RSV) is a common cause of lower respiratory tract infection (LRTI) and is responsible for a high burden of hospital admission and mortality in children. RSV–LRTI is also associated with long-term ...

Often dismissed as just another common cold, RSV can be deadly, especially for infants and older people. Hannah and her twin ...

As the 2024-2025 respiratory virus season gets under way, statewide infectious disease experts urge everyone in Oregon to ...

Most people experience mild RSV reinfections throughout their lifetime, particularly during respiratory virus season (November to March in Canada). People are at higher risk if they are older than 75 ...

RSV, or respiratory syncytial virus, is a common cause of coughs and colds which can also lead to severe lung infections like pneumonia and infant bronchiolitis – conditions which are highly ...

Background: Respiratory syncytial virus (RSV) vaccines could reduce disease burden and costs in older Canadian adults, but vaccination program cost-effectiveness is unknown. We evaluated the ...

Arexvy is approved for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older and in individuals 50 through ...

Respiratory syncytial virus (RSV) is the most important cause of infantile bronchiolitis and pneumonia. It is ubiquitous, with most children acquiring their primary infection within the first year ...